Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,606,502	$ 5,478,113
Research and development tax incentive receivable	309,825	433,852
Prepaid assets and other current assets	592,142	1,678,353
Total current assets	3,508,469	7,590,318
Operating lease right-of-use asset, net	57,990	119,529
Property and equipment, net	1,639,526	1,999,781
Investment in Vaxanix	1,776,746
Note receivable - Augmenta		2,310,000
Other assets	95,322	7,688
Total assets	7,078,053	12,027,316
Current liabilities:
Accounts payable	1,644,361	958,442
Accrued liabilities	1,993,355	1,285,586
Deferred research grant revenue	250,698	101,000
Current portion of operating lease liability	52,403	83,512
Total current liabilities	3,940,817	2,428,540
Operating lease liability, net of current portion		31,742
Total liabilities	3,940,817	2,460,282
Commitments and contingencies
Stockholders’ equity:
Common stock; $0.001 par value, 180,000,000 shares authorized; 3,538,248 and 2,370,000 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	3,538	2,370
Additional paid-in capital	135,391,296	128,044,509
Accumulated other comprehensive loss	(166,647)	(148,192)
Accumulated deficit	(132,090,951)	(118,331,653)
Total stockholders’ equity	3,137,236	9,567,034
Total liabilities and stockholders’ equity	$ 7,078,053	$ 12,027,316